VC-CBCS Study protocol v 7.0—16Nov 2021  
  
 
A Pilot Feasibility Testing of a Small Randomized Controlled Trial to Evaluate a 
Telemedicine Stress Management and Lifestyle Group Intervention for Patients 
with Symptomatic Chronic Hepatitis C  
 
Study Protocol: Version 7.0, 16Nov 2021  
 
NCT Identified Number: [STUDY_ID_REMOVED]  
 
Primary Investigator:  
Donna M. Evon, PhD  
  Professor of Medicine 
8010 Burnett -Womack, CB#: 7584  
Division of Gastroenterology and Hepatology  
Department of Medicine  
University of North Carolina  
Chapel Hill, NC 27599- 7584 
Telephone: (919) 966 -6732 
Email: Donna _Evon@med.unc.edu  
 
Sponsor: The University of North Carolina at Chapel Hill  
 
 Grant Number: 1R21NR017908 - 01A1  
 
Funded by: National Institutes of Health – National  Institute of Nursing Research (NINR)  
 
Version Number:  v.7.0 
 
Version Date: 1 6 Nov 2021 
 
 
  
 
 
 
 
 
VC-CBCS Study protocol v 7.0—16Nov 2021  
 STUDY PROTOCOL  
DOCUMENT HISTORY  
 
Document  Date of Issue  Summary  
Original Version 
of Protocol, 
Version 1.0  22Sept2019  • First version of the protocol  : 22Sept2019  
• Submitted to UNC IRB : 22Sept2019 
• Approved by IRB  
• Submitted to NINR   
Version 2.0  07Feb2020  The following changes have been made:  
• Updated:  
o exclusion criteria  
o reimbursement procedures  
o randomization procedures   
o salivary cortisol procedures  
o research team information 
• Removed:  
o use of study website ; replaced with a Google drive 
o use of Zoom; study will only utilize WebEx  
• Clarified research staff roles in study procedures  
Version 3.0  20Mar2020  **During the COVID -19 outbreak , Wave 1  is allowed  to forego saliva 
sample testing, if necessary, pending allowed research operations ** 
 
Additionally, t he following changes have been made:  
• Recruitment and consenting procedures clarified and 
updated to include verbal telephone consent  
• Changed randomization groups so that Group 1 will consist 
of 7 patients and Group 2 will consist of 9 patients; total 
number of participants remains the same (n=32)  
• Updated location of some study procedures to be conducted 
in a private area and for study documents to be stored in 
locked, secure area  
• Minor updates to IT’s role and responsibility   
• Typographical and grammatical errors corrected throughout  
 
Version 4.0  18May2020  The following changes have been made:  
• Removed:  
o use of Google drive ; replaced with UNC OneD rive 
• Typographical, formatting,  and grammatical errors corrected 
throughout  
Version 5.0  09Jul2020  Replacing UNC OneDrive with Google Drive due to technical issues.  
Version 6.0  15Dec 2020  The following changes have been made:  
• Updated order of study outcomes  
• Typographical, formatting, and grammatical errors corrected 
throughout  
 
Version 7.0  16Nov2021  Updated study outcomes  
  
  
VC-CBCS Study protocol v 7.0—16Nov 2021  
  
Table of Contents  
 
1 BACKGROUND AND RATIONALE  ......................................................................................................................... 5 
2 STUDY AIMS  ............................................................................................................................................................... 6 
3 STUDY DESIGN  .......................................................................................................................................................... 7 
3.1 Study Design  .......................................................................................................................................................... 7 
3.2 Study Participants ................................................................................................................................................... 7 
3.3. Inclusion/Exclusion Criteria  .................................................................................................................................. 7 
3.3.1. Inclusion  .........................................................................................................................................................     7 
3.3.2. Exclusion  ............................................................................................................................................................ 7 
4 RECRUITMENT  ........................................................................................................................................................... 7 
5 INFORMED CONSENT PROCESS............................................................................................................................. 8 
6 SCREENING FOR VC -CBCS ELIGIBILITY  ............................................................................................................. 8 
6.1 Phase I Screen  ........................................................................................................................................................ 9 
6.2 Phase II Screen:  ...................................................................................................................................................... 9 
6.3 Screening Data:  ...................................................................................................................................................... 9 
7 REIMBURS EMENT ..................................................................................................................................................... 9 
8 RANDOMIZATION  ................................................................................................................................................... 10 
9 STANDARD CARE  .................................................................................................................................................... 10 
10 VC -CBCS GROUP INTERVENTION  ..................................................................................................................... 10 
10.1 Tentative Conceptual Model of the VC -CBCS  .................................................................................................. 10 
Figure 1: Conceptual Model of VC -CBCS Intervention  ............................................................................................ 11 
10.2 Conducting the VC -CBCS Group Intervention  ................................................................................................. 11 
Table 1: Content and structure of 14 VC -CBCS group modules  ................................................................................... 12 
Figure 2: How does the VC -CBCS help to improve Liver Health and Wellness? ..................................................... 12 
10.3 Technology Training and iPads and Review of Rules of Group Engagement and Privacy  ............................... 13 
10.4 Iterative changes to VC -CBCS intervention  ...................................................................................................... 13 
11 DATA COLLECTION ASSSEMENT SCHEDULE ................................................................................................ 13 
11.1 PRO Assessments ............................................................................................................................................... 13 
11.2 Salivary Cortisol ................................................................................................................................................. 13 
11.3 VC -CBCS Process Assessments  ........................................................................................................................ 13 
Table 2: Data Collection  Schedule  ............................................................................................................................. 14 
12 MEASURES TO EVALUATE FOUR SPECIFIC AIMS......................................................................................... 14 
12.1 Study and Intervention Feasibility (Aims #1, #2)  .............................................................................................. 14 
12.2 Patient Satisfaction (Aim #3)  ............................................................................................................................. 14 
12.3 Patient -Reported Outcome Measures (Aim #4)  ................................................................................................. 15 
13 PRIMARY  FEASIBILITY OUTCOME MEASURES ........................................................................................ 15 
14 PRIMARY PATIENT -REPORTED OUTCOME MEASURES .......................................................................... 15 
14.1 PROMIS Global Health Status Mental Health Mean T -Score  ........................................................................... 15 
14.2 PROMIS Global Health Status Physical Health Mean T -Score  ......................................................................... 15 
VC-CBCS Study protocol v 7.0—16Nov 2021  
 14.3 PROMIS Depression Mean T -score ................................................................................................................... 15 
14.4 PROMIS Anger Mean T -score  ........................................................................................................................... 15 
14.5 PROMIS Anxiety Mean T -score  ........................................................................................................................ 15 
14.6 PROMIS Fatigue Mean T -score ......................................................................................................................... 15 
14.7 PROMIS Sleep Disturbance Mean T -score  ....................................................................................................... 15 
14.8 PROMIS Pa in Interference Mean T -score  ......................................................................................................... 15 
15 SECONDARY PATIENT -REPORTED OUTCOME MEASURES  .................................................................... 15 
16 SECONDARY CLINICAL OUTCOMES  ............................................................................................................ 16 
17 EXPLORATORY PATIENT -REPORTED OUTCOME MEASURE  ................................................................. 17 
18 EXPLORATORY STRESS BIOMARKER OUTCOME  ..................................................................................... 17 
20 PATIENT SOCIODEMOGRAPHICS  .................................................................................................................. 17 
21 PROTOCOL FIDELITY  ....................................................................................................................................... 17 
22 ELECTRONIC DATA CAPTURE AND SECURE STORAGE  .............................................................................. 18 
23 DATA ANALYSIS  ................................................................................................................................................... 18 
23.1 Statistical Analysis Overview  ............................................................................................................................ 18 
23.2 Aim 1: Feasibility of conducting a RCT  ............................................................................................................ 18 
23.3. Aim 2: Feasibility of intervention delivery  ....................................................................................................... 18 
23.4 Aim 3: Patient satisfaction and acceptability  ..................................................................................................... 19 
23.5 Aim 4:  Explore changes in patient outcomes, mediators and intervention targets, as well as temporal 
associations and strength of associations among variables in a preliminary conceptual model, to inform a future 
efficacy trial  ........................................................................................................................................................ 19 
24 STUDY CONDUCT  ................................................................................................................................................. 19 
25 DATABASE RETENTIO N ...................................................................................................................................... 19 
26 DATA AND SAFETY AND MONITORING PLAN............................................................................................... 20 
26.1 Procedures for Adverse Events (from DSMPv2.0 - 27Sept2019)  ...................................................................... 20 
27 RESEARCH TEAM  .................................................................................................................................................. 20 
28 GLOSSARY OF TERMS .......................................................................................................................................... 21 
29 REFERENCES .......................................................................................................................................................... 22 
 
  
VC-CBCS Study protocol v 7.0—16Nov 2021  
 1 BACKGROUND AND RATIONALE  
 
Hepatitis C viral (HCV) infection has a tremendous impact on individual and public health . HCV 
affects over 3 million Americans, leading to 15,000 deaths per year from liver failure, cirrhosis, and liver cancer.
48 Up to 20% of patients will develop cirrhosis49,50 and 10- 20% will develop decompensated 
cirrhosis or cancer. Though typically associated with the liver, HCV is a multi -faceted systemic disease  
also affecting multiple organs and systems51 and associated with many extrahepa tic disorders (EHDs) 
including musculoskeletal, endocrine, neuropsychiatric, and cardiac disorders.13,52 Our PROP UP data 
suggest that HCV patients have an average of 4 comorbidities (range: 0 -15), the most prevalent being 
musculoskeletal pain and high blood pressure (50%), psychiatric (44%), sleep disturbance (31%), and 
diabetes (20%).53 Patients report clinical distress from somatic and neuropsychiatric symptoms with 
fatigue, depression, sleep issues and chronic pain most common.16-20,54 Not surprisingly, HRQOL is 
impaired.21,22  While HCV may lead to chronic systemic i nflammation with neuropsychiatric and somatic 
sequalae,13,54,55  other factors also contribute to poor health including social determinants of poor 
health.27 Unhealthy lifestyle habits also perpetuate chronic illness56-58 and confer greater risk for liver 
disease, m etabolic syndrome, and death.28,59 Even in patients cured of HCV, many remain symptomatic 
and at risk for cirrhosis or liver cancer if healthier lifestyles not adopted.24 The economic burden of HCV 
is >$10 billion annually when accounting for costs of liver disease, EHDs, low HRQOL and loss of work 
productivity.60 
 People who have been infected with HCV may benefit from comprehensive multi -modal 
interventions to improve important patient outcomes.  Comprehensive mult i-modal psychosocial 
interventions that provide stress management, coping skills, and lifestyle modification for the HCV population are nonexistent. Despite chronic health risks, multi -morbidities, life stress and unhealthy 
behaviors, all of which amplify illness, virtually no psychosocial interventions have been developed for the HCV population. However, evidence- based psychosocial interventions have improved diverse 
health outcomes in people with other chronic illnesses (e.g., cancers, diabetes, chronic f atigue, pain, 
HIV). Group -based psychosocial interventions that emphasize cognitive behavioral (CB) stress 
management (SM) coping skills improve psychological and physical health outcomes
30,31,35- 37,61 and are 
associated with change in multiple stress -related immunological indices (e.g., CD4 viral count, cortisol 
patterns, proinflammatory cytokines).31-34 Improvements in immune functioning often correlate with 
symptom reduction.62-65 In one of the only psychoneuroimmunological studies conducted in HCV, 
associations were found between patients’ depression, anxiety, fatigue, and pain levels and high levels 
of inflammatory proteins, accounting for up to 40% of the variance in symptoms.14  
 
Extrapolating from this strong empirical base built in other chronic diseases, liver disease researchers 
need to determine if psychosocial interventions confer similar benefits to liver patients. Given the 
prevalence of HCV and the number of patients who r emain symptomatic or may progress to advanced 
liver disease, comprehensive, holistic liver care should integrate health promotion interventions into current practice, over and above a myopic focus on just viral eradication and medical management  of 
cirrhosis . The ideal intervention would include stress management, coping skills, and health behavior 
modifications , which , in turn,  may improve symptoms , 
66 HRQOL, and disease markers.29,67,68  Within 
this secondary prevention model, modifying psychological and physiological stress and lifestyle 
behaviors in symptomatic or at -risk liver patients, may yield substantial health benefits. As such, we 
sought to tailor evidence -based psychosocial interventions to the needs of HCV patients to improve 
physical and psychological health outcomes.  
 
Multiple patient barriers exist to attending in-person interventions. Patient -level barriers to 
accessing traditional face- to-face healthcare services are enormous and include travel, geographical, 
financial, transportation, and illness barriers.69 This dilemma is particularly salient in rural areas where 
healthc are access is poor.39,70 During pilot -testing of the in-person group -based Cognitive Behavioral 
Coping Skills (CBCS -HCV) intervention developed for patients infected with chronic HCV , patients who 
declined participation cited travel distance and transportation barriers.6,38 No patients declined due to 
lack of interest. Many commented that the intervention seemed valuable, but that in -person sessions 
were impractical. Other psychosocial interventions for patients with HCV that require in -person  
sessions have also suffered from low recruitment,71,72 convincing us that alternativ e modes of delivery 
VC-CBCS Study protocol v 7.0—16Nov 2021  
 must be explored to increase access to treatment, especially in rural states  like North Carolina (85 out 
of 100 counties are designated rural) . 
 
Delivering interventions via videoconferencing (VC) technology is a cutting -edge  alternative to 
in-person delivery. Healthcare delivery is moving rapidly in the direction of utilizing innovative 
technologies to overcome myriad inefficiencies costs, and barriers that currently stymy the US 
healthcare system.39-42  “Telehealth” is a burgeoning sector of healthcare delivery in the US. VC 
technology has numerous potential advantages for delivering interventions directly from providers to patients situated in their  own homes .
73 Geographical, financial, and unreliable transportation barriers 
are eliminated. Patients who are too ill to travel can participate.74 Reducing patient barriers may lead to 
higher rates of study enrollment and attendance. Recruitment for in- person interventions is often lower 
than 40%71, while recruitment for phone - or web- based interventions can range from 57 -94%.7,75- 77 
Higher attendance may increase in tervention “dose,” which in turn, may increase clinical 
effectiveness.75,78 Patient satisfaction with VC has been shown to be very high and often is preferred 
over in-person  sessions due to overcoming many obstacles .5,75,78,79 Importantly, skill -based 
psychosocial treatments are commonly delivered in a group format, and can be highly economical and 
efficient  for providers and healthcare systems . Delivering psychosocial skill -based interventions in 
group formats also capitalize on positive therapeutic pr ocesses such as group cohesion, peer support, 
bonding and social persuasion.80 In order to retain cost -efficiency and beneficial processes of group -
based therapy, an ideal telehealth version of the CBCS -HCV would be delivered via VC technology to a 
group of HCV patients, participating from the comfort of their own home.  While many telehealth 
modalities are being investigated, most are 1:1 prov ider-to-patient; very few have investigated 
delivering a group -based intervention to multi -end-user patients  in their own separate home s. 2-5 
 Since the CBCS -HCV  is a skill-based intervention  and group format is often the  standard of care  for 
these types of interventions , multi- user VC delivery may be a cutting edge and efficient system to 
deliver holistic interventions to patients who might not otherwise have access to services due to illness 
or transportation barriers. Pilot testing the CBCS group- based intervention via a state -of-the-art VC 
multipoint platform is a highly innovative and a logical extension of our previous work. Delivering the 
CBCS -HCV via VC may decrease patient barriers, increase access to care, and be clinically effective. 
However, the feasibility, tec hnical issues, patient satisfaction, and preliminary outcomes require pilot -
testing to determine if a larger efficacy trial is warranted.  
 
We propose to conduct a pilot feasibility study of a small randomized controlled trial (RCT) to evaluate 
the CBCS del ivered via videoconferencing (herein referred to as “ VC-CBCS ”) compared to patients in 
standard of care (SC) with a representative sample of 32 symptomatic HCV patients, to address the following specific aims:  
 
2 STUDY AIMS  
 
Aim 1: Evaluate the feasibility of conducting a RCT of the VC -CBCS, quantified as the proportion of 
patients (a) approached vs. consented vs. enrolled/randomized vs. retained, and (b) who complete data 
collection;  
Aim 2: Evaluate the feasibility of intervention delivery via VC, quantified as (a) the proportion of 
sessions attended by participants and (b) frequency and nature of technical, logistical, or participant 
problems;  
Aim 3: Evaluate patient acceptability and satisfaction;   
Aim 4: Explore changes in patient outcomes, mediators and intervention targets, as well as temporal 
associations and strength of associations among variables in a preliminary conceptual model, to inform a future efficacy trial.  
 
 
VC-CBCS Study protocol v 7.0—16Nov 2021  
 3 STUDY DESIGN  
 
3.1 Study Design  
This pilot feasibility study was designed as a preparatory two- arm small randomized controlled trial 
(RCT ) with a total enrollment of  32 participants assigned by randomization to VC -CBCS  (n=24)  or SC  
(n=8)  to address the specific aim.  
 
3.2 Study Participants  
Participants (n=32) will be a representative sample of adult patients, age 21 or older, w ho have or h ad 
a diagnosis of chronic HCV  
 
3.3. Inclusion/Exclusion C riteria  
  
3.3.1. Inclusion  
• Age 21 and older;  
• Medically cleared by hepatology ; 
• Patients who are currently or were previously diagnosed with chronic HCV;  
• Evidence of ongoing symptoms, stress, or unhealthy lifestyle habits, defined as a score of 
greater than or equal to 4 on a scale 0( none) - 10 (severe) on two or more numeric rating scale 
questions (see Screening Form  1); 
• Able to read and speak English.  
3.3.2. Exclusion  
• Decompensated liver disease (Childs Pugh C) judged by hepatologist or recorded in patient 
medical record;  
• Life expectancy of <12 months estimated by hepatologist;  
• Has had a liver transplant or is on the waitlist for a transplant ; 
• Severe alcohol  or substanc e use disorder, psychiatric disorder or cognitive impairment that is 
likely to interfere with the ability to participate in telehealth groups and follow guidelines about group 
participation as judged by the Hepatology provider or research staff using a two- tiered research 
screening process (See Section 6);  
• Lack of private, quiet space in home in which to participate in VC -CBCS sessions ; and  
• Unwilling to have group sessions audio- recorded.  
4 RECRUITMENT  
 
A two-pronged recruitment strategy will be utilized (primary: in person in liver clinic; secondary: over the 
phone).  Patient s will be recruited from the outpatient liver clinics or by phone if referred by a hepatology 
provider.   
 
For every patient approached for recruitment, a minimal amount of data will be stored in a REDCap 
Screening Database, separate from the REDCap Research Database. The Screening Log will include: 
name, MRN, phone number, race, sex , age, and reason for exclusion or not proceeding forward with 
consent process. Name, MRN and phone number will be deleted after recruitment ends. De- identified 
race, sex, and age are retained to satisfy CONSORT guidelines for future publications.  
 
Patients will be recruited in 4 waves. Although we seek to enroll/randomize a total of 32 patients with 24 
randomized to VC -CBCS and 8 randomized to SC, we will over -consent to accommodate for patients 
who are deemed ineligible during the screening process or who withdraw consent prior to enrollment . 
The overall  3:1 randomization sche me allows us to examine feasibility of randomization while allowing 
us to intensively examine the VC -CBCS group.  
 
VC-CBCS Study protocol v 7.0—16Nov 2021  
  
5 INFORMED CONSENT PROCESS  
 
The informed consent process will take place in person in the GI liver clinic or over the phone .  
1. In-Person Consent : Interested patients will be introduced to study staff  and taken to another private 
room to engage in the informed consent process and screening assessment. Interested and eligible 
patients will sign and date/time the consent forms, staff signs/dates and th e patient will be  provided a copy . 
The informed consent process will be documented for each consented patient.  After written consent is 
obtained, staff can begin to screen and collect data from the patient.  
2. Over -the-Phone Consent : When a prospective patient is re ferred by a hepatology provider to the 
study team , the staff  will pre -screen the patient using a limited waiver of HIPAA  approved by the UNC IRB. 
Study staff will access patient medical records for contact information and conduct a brief eligibility  
assessment ( e.g., HCV  diagnosis , > age 21, English speaker). Staff will contact patients via phone to 
discuss the study and consent documents. Interested patients will be consented with a verbal telephone 
consent and  then be emailed or mailed a HIPAA authorization with a pre -paid envelope for return. The 
study team will then review the HIPAA authorization with the participant and instruct the participant to sign 
and date and return to study in provided envelope. Participants will be considered consented if  and when 
they agree to the telephone verbal consent, but their medical records will not be accessed until signed 
HIPAA authorization is received by the study team.  
Whether consented in- person or over the phone, all components of the informed consent process will be 
reviewed and documented per federal ( https://www.hhs.gov/ohrp/regulations -and-
policy/regulations/finalized- revisi ons-common -rule/index.html ) and institutional guidelines 
(https://www.hhs.gov/ohrp/regulations -and-policy/regulations/finalized- revisions -common-
rule/index.html ) and relevant Good Clinical Practice Guidelines from the I nternational Conference on 
Harmonisation. I ssues of privacy, confidentiality, and time commitment will be discussed. Patients will 
verbalize understanding that research parti cipation in voluntary and they can choose to stop or decline 
at any time without penalty. They can refuse to participate,  and this decision will not affect their medical 
care at UNC. They can refuse to answer any study or interview question. The study staf f obtaining 
consent  will allow ample time for patients to ask questions and express full understanding of the study.  
 
A checklist of the informed consent process will be retained for all consented patients. All signed 
consent forms will  be uploaded to the REDC ap database and hard copies retained in a secure location. 
Data collection, enrollment, randomization will not commence until all necessary consent s have  been 
obtained.   
  
Patients will c onsent  to participate in the following:  
1) review of electronic medical r ecords for clinical data;  
2) undergo screening process and collection of screening data;  
3) participation in a 14- week VC -CBCS group intervention delivered via home technology or study -
loaned tablets that patients  may return at the end of the study;  
4) participation in a group exit interview following participation in the intervention;  
5) completion of self -report surveys throughout the study;  
6) collection of saliva samples at pre - and post -intervention; and  
7) REDCap storage of email address, mailing address, phone numbers for self and a loved one in case 
of lost to follow -up. This  information is required for  REDCap data collection of surveys, reimbursement 
to patients and communication throughout the study.  
 
6 SCREENING  FOR VC -CBCS ELIGIBILITY  
To enhance intervention fidelity, group cohesion/dynamics, and adherence to the protocol, a two- tiered 
screening process will be conducted to enroll eligible patients. Patients will be consented prior to engaging in the screening assessment. Phase I of screening will occ ur with study staff  in-person in the 
liver clinic or over the phone. Phase II is conducted by the study PI.  
VC-CBCS Study protocol v 7.0—16Nov 2021  
 6.1 Phase  I Screen: Staff will conduct the initial screening  for I/E criteria using three Screening Form s 
located in a separate REDC ap database for screening data only . The patient must meet all inclusion 
criteria including "evidence of ongoing symptoms, stress, or unhealthy lifestyle habits as defined by a score 
of ≥ 4 on a rating scale from 0 –  10, for ≥ 2 symptoms, perceived stress, or lifestyle habits" and must not 
meet exclusion criteria, including severe current alcohol, substance use or psychiatric disorder likely to 
interfere with group dynamics or adherence to study protocol. The Screening Form s will in clude items to 
determine inclusion/exclusion criteria, including assessment of physical and mental symptoms, stress level, 
and lifestyle habits. Alcohol, substance use, and psychopathology will be assessed using questions from 
validated instruments, including the Alcohol Use Disorders Identification Test (AUDIT), the S ubstance 
Abuse and Mental Illness Brief Symptom Screener (SAMISS) and additional screening items developed by 
the PI. Screening will take place in- person in private exam room in clinic, or ove r the phone.  
 
6.2 Phase  II Screen:  The second phase of the two- tiered screening process will be conducted by the PI  (a 
licensed clinical psychologist at UNC Healthcare)  who will review the Phase I screening forms and discuss 
the prospective participant with the screening coordi nator who conducted the consent and screen. If the 
patient meets I/E criteria and screens negative for severe current alcohol, substance use or psychiatric 
disorders, the patient will be approved for enrollment into the study based on Phase I screening data. 
When ambiguity or uncertainty arises regarding the patient’s  eligibility related to current alcohol, substance 
use or psychiatric disorders, the  PI will conduct a brief clinical interview with a prospective participant over 
the phone . Based on the two- tiered screening process, t he PI will adjudicate final decisions regarding study 
eligibility.  
 
The goal of the two -tiered s creening process is to ensure that patients (1) are appropriate for a group 
therapeutic setting; (2) are at low risk for verbal behaviors that will interfere with or sabotage group 
cohesiveness/support  which is critical to the success of psychosocial interventions ; (3) are able to adhere 
to the study protocol and rules of engagement; and (4) with acti ve and severe psychiatric or substance use 
disorder s are referred for more appropriate individual treatment in their local  community .  
 
Patients judged to have untreated or more severe psychopathology will receive a referral from the PI to 
more appropriate mental health/addiction services in their local community.  
 
6.3 Screening Data:  Data from the three Phase I Screening Form s will be stored in  a REDCap screening 
database separate from the Research Data . For patients who are ineligible or decline to participate, their 
name, MRN, age, sex, race,  and reason for ineligibility/refusal will be retained in the s creening REDC ap 
database. All other screening data will be deleted at the end of the study. Name and M RN are retained 
during the study for staff to identify previously recruited but ineligible patients. Name and MRN of non-
enrolled pat ients will be deleted from the s creening database after recruitment ends.  The hard copy Phase 
II Brief Clinical Interview f orms will be shredded after recruitment ends. Once the screening data are 
deleted or de- identified, only sex, race, age, and reason for non- enrollment patients will be retained until all 
data are published, to satisfy CONSORT guidelines. Once final data ar e published, the REDCap Screening 
database will be deleted. For patients who are eligible and enrolled, data from the three S creening Forms 
will be e xported into the Research REDCap database to describe characteristics of the cohorts.  
 
7 REIMBURSEMENT  
 
Participants in both conditions will be reimbursed $25 for four patient -reported outcomes (PROs) 
assessments and two days of salivary sample collection. Completion of PROs during each assessment 
period will take 20 -30 minutes. Patients randomized to VC -CBCS will be reimbursed $25 to participate in 
an exit focus group. For reimbursement of VC -CBCS sessions, participants will be reimbursed for cellular 
and wi -fi data plans, if needed for iPad use, and  will be given t wo options: (1) retain the iPad (worth $300) 
after the study ends; (2) receive a rechargeable Visa gift card at the beginning of the study that will be 
recharged with $300 after the intervention ends and iPad is returned.  Participants will check their 
preference for one of these t wo options on the consent form.  Participant preferences will be tracked in a 
Reimbursement Log to inform reimbursement  options  for a future RCT.  
VC-CBCS Study protocol v 7.0—16Nov 2021  
  
8 RANDOMIZATION  
 
Four groups  of patients will be randomized and  will consist of 7 -9 patients each. The groups are as follows:  
 
• Group 1 - 7 patients with 5 randomized to VC -CBCS and 2 to SC;  
• Group 2 - 9 patients with 7 randomized to VC -CBCS and 2 to SC;  
• Groups 3 and 4 -  8 patients each with 6 randomized to VC -CBCS and 2 to SC  each group .  
 Once each group meets their respective necessary number of patients, they will be randomized. We will 
use these r andomization procedures  for a total of 24 participants randomized to VC -CBCS and 8 
randomized to SC  and overall 3:1 ratio. A computer -based procedure for permuted- block randomization 
and concealment will be implemented  by non -study staff. No study personnel will have access to the 
randomization schedule. The computer -generalized randomization scheme will automatically randomize 
patients who are enrolled to one of the two group  assignment s after each wave is enrolled.  Participants will 
be subsequently called and informed of group assignment.  
 
9 STANDARD CARE  
 
Patients randomized to the SC condition will be managed per standard HCV and liver disease 
management guidelines by the UNC hepatologists. C linic appointments, lab tests and procedures will be 
conducted at the provider’s discretion.  Depending on severity of liver disease, patients are typically 
followed every 6- 12 months by Hepatology. Research staff will have minimal contact with SC participants 
except during PRO assessment windows  and two sali va sample collections . Study staff will extract clinical 
data from electronic medical records up to 6 months post -intervention.   
 
10 VC-CBCS GROUP INTERVENTION  
 
The CBCS is based on Cognitive Behavioral Theory (CBT) and the Informational -Motivation -Behavi oral 
skills (IMB) theoretical framework.
83,97,101 The intervention modules will be delivered over 14 sessions, each 
with a duration of 90 to 120 minutes to allow for the practice of a newly introduced skill. Each session will 
incorporate comprehensive information on evidence- based sk ills for health behavior change and stress 
management. The modules will also incorporate CBT skills and educational materials developed by federal 
agencies.102-104 Sessions will include background information and rationale, recommended behavioral skills 
and will utilize strategies such as peer discussion and support, goal -setting and motivational enhancement 
techniques to increase commitment and motivation for positi ve lifestyle changes.  
 
10.1 Tentative C onceptual Model of the VC -CBCS  
As a pilot feasibility study, we are not testing the intervention model depicted in Figure 1  below. We are 
mapping out a hypothetical model  to gather preparatory information to inform a subsequent efficacy trial: 
The model helps to identify survey items that need to be developed or used to measure intervention targets 
and mediators. P ilot-testing w ill help determine the optimal frequency of data collection of targets and 
mediators while balancing patient burden. Pilot -testing will help with e xploration of preliminary associations  
(aim #4 ) among variables to understand their temporal relationships and strength of associations . Figure 1  
describes how each intervention session will attempt to target information- motivation -behavioral skills 
(CBT, stress management, health behaviors). Didactic information  is provided to build ‘buy -in’. B ehavioral 
skills  are taught and practiced during session and as homework . Sessions wrap up with round robin 
discussion of patients ’ SMART goals for the week and why a patient is motivated to work on this goal 
(fosters  personal and social motivational enhancement, commitment, social persuasion,  and healthy 
norm s). Intervention targets may improve both psychological and physiological stress, healthy behaviors,  
and medication adherence, which may operate as mediators/mechanisms of change, but may also serve as intermediate outcomes in and of themselves. These medi ators or intermediate outcomes may in turn, 
improve health outcomes, including overall health status and  symptoms. It is plausible that behavioral 
changes and stress reduction may improve clinical disease outcomes. In this pilot study, we will attempt to 
collect aspartate aminotransferase (AST) and alanine aminotransferase (ALT) from patients electronic 
health records (EHRs) to determine the feasibility of collecting standard clinical data from the EHRs, and if 
VC-CBCS Study protocol v 7.0—16Nov 2021  
 feasible, explore potential pre-post change i n these two markers of liver inflammation. We will  also extract 
additional clinical variables of interest that may be relevant to a future efficacy trial, such as hemoglobin 
A1C in diabetic patients (~ 20% of sample) , body weight (kg)  and other laboratory tests.  If a future efficacy 
trial finds the VC -CBCS to have short -term benefits on patient outcomes, it would behoove us to 
investigate the potential for longer -term benefits on subjective health, liver disease, and other comorbid 
conditions, as has been shown in other medical populations.106-109 
 
Figure 1: Conceptual Model of VC -CBCS Intervention  
 
 
 
 
10.2 Conducting the VC -CBCS Group Intervention  
Sessions will be delivered using the UNC School of Medicine’s University -approved, HIPAA -compliant 
WebEx ® videoconferencing system. WebEx ® is an application that i s widely used for web and 
videoconferencing meetings and includes multi -point audio and video communication, screen sharing, 
video and audio recording, and telephone bridging. The research team will work closely with the UNC 
School of Medicine Information Technology Security Team  on all aspects of delivering the VC -CBCS 
including patient instructions, iPad set up, and remote data cleaning.  Each group member will join the 
virtual group from their home using their choice of home audio- visual technology or study -provided iPads  to 
simultaneously observe and interact with the group facilitator and other group members (“Brady Bunch” 
style).  
 
All modules follow the same three -part organization (Table 1) :  
(1) Introduction and practice of new relaxation skill  
(2) Review of previous weeks ’ information, skill, and SMART goals  
(3) Information, acquisition,  and practice of new skills. Didactic information is followed by practicing skills to 
aid in cognitive behavior change. Mo tivational enhancement strategies  are used to increase personal and 
social motivation.97,101 SMART goals are used to promote achievement of weekly goals that are specific, 
measurable , action- oriented, realistic,  and time -based.  
 
VC-CBCS sessions will be led by a  Masters -level therapist with experience in facilitating groups, protocol -
based and evidence- based treatments,  and adept at motivational enhancement strategies.  
 
VC-CBCS patient materials will be stored on iPads and uploaded to a secure  Google Drive  shared  drive 
containing no identifying information. Materials include the Patient Workbooks, relaxation audio -recordings, 
technical instructions, and link to unique REDCap application system . Hard copy Patient Workbook s will 
also be mailed to each participant prior to the first session for use during sessions.   
  
 

VC-CBCS Study protocol v 7.0—16Nov 2021  
  
 
Table 1: Content and structure of 14 VC -CBCS group modules  
 
Figure 2: How does the VC -CBCS help to improve Liver Health and Wellness?  
 
 
Mod Part 1:  
 Relaxation Training  Part 2:  
Review and Application of Previous 
Skills  Part 3:  
Training in New Topic and Skills  
1 Progress. Muscle Relax. 
(PMR -6) Introductions, Group Expectations; 
Confidentiality  Overview of Liver Functions, Liver 
Conditions, and Targets of the VC -CBCS 
Intervention  
2 Diaphragmatic Breathing & 
PMR -4 Overview of Liver Functions, Liver 
Conditions, and Targets of the VC -CBCS 
Intervention  Love Your Liver: Healthy Nutrition and 
Hydration  
3 Diaphragmatic Breathing & 
Mindfulness  Love Your Liver: Healthy Nutrition and 
Hydration  Physical Activity for the Liver  
4 PMR -4 & Healing Wellness 
Imagery  Physical Activity for the Liver  Sleep Hygiene & Managing Sleep 
Problems  
5 Diaphragmatic Breathing & 
Light Imagery  Sleep Hygiene & Managing Sleep 
Problems  Taking medications as prescribed & 
Maintaining Healthy Lifestyle  
6 Deep Breathing & Immune 
Guided Imagery  Taking medications as prescribed & 
Maintaining Healthy Lifestyle  Stress Awareness & Appraisal  
7 Diaphragmatic Breathing & 
Autogenic Training  Stress Awareness & Appraisal  Automatic Thoughts & Cognitive 
Distortions  
8 PMR -4 & Self -Forgiveness 
Affirmation Script  Automatic Thoughts &  
Cognitive Distortions  
 Cognitive Restructuring  
9 Counting Breaths & Passive 
PMR  Cognitive Restructuring  Coping with Stress & Symptoms  
10 4-7-8 Breath & Mindful 
Movement  Coping with Stress & Symptoms  Cognitive -Behavioral Skills for 
Depression - Behavioral Activation & 
Pleasurable Events  
11 Short Body Scan  Cognitive -Behavioral Skills for Depression 
– Behavioral Activation & Pleasurable 
Events  Activity -Rest Cycles  
12 Mini Practices & Self -
Acceptance Affirmation 
Script  Activity -Rest Cycles  Anger Prevention & Management  
13 Mindfulness Meditation & 
Deep Breathing  Anger Prevention & Management  Assertive Communication;  
Interpersonal Effectiveness  
14 Group Choice  Assertive Communication; Interpersonal 
Effectiveness  Maintenance of Positive Lifestyle 
Changes & SMART Goals;  
Group Program Review  
VC-CBCS Study protocol v 7.0—16Nov 2021  
 10.3 Technology Training and iPads and Review of Rules of Group Engagement and Privacy 
If patients do not have appropriate audio- visual technology on home computers/laptops, they will be 
provided a study  iPad and funding for cellular or internet data plans duri ng the duration of the study. The  
UNC School of Medicine Information Technology Services (ITS; https://its.unc.edu/ ) staff and the 
national broadband map  (https:// www.bro adbandmap.gov/)  will be used to determine best data plans for 
each participant. The iPads wi ll be set -up and secured by SOM ITS. P articipants will receive iPad, 
internet, and REDC ap data collection training from the research staff with ITS support prior to the initial 
session. A conference line will be available if VC disconnection occurs. All technical issues will be 
tracked  as part of reporting feasibility outcomes. Our consultants will share best practices for deliver ing 
tele-mental health.45,105 An SOM ITS e xpert will be available during each cohort launch to troubleshoot. 
Although patients will be provided iPad and data plans, WebEx ® is available for Android and iOS smart 
phones . A few patients may be allowed to participate via smartphone to examine patient satisfaction and 
outcomes using smartphones, which could be more scalable in future projects. They can complete their 
post-session  surveys at the conclusion of each session or at their convenience during the assessment 
window  (7 days ).  
 
During the WebEx® training with study staff , privacy and confidentiality issues related to engagement in 
home- based virtual groups with other participants will be thoroughly discussed. A copy of group rules 
will be reviewed. Participants will need to provide verbal assurance that they will respect the group 
privacy rules.  
 
10.4 Iterative changes to VC-CBCS intervention 
Based on patient feedback and lessons learned, the research team will modify aspects of the VC -CBCS in -
between the four waves. Changes may be made based on feasibility data, patient satisfaction ratings,  and 
impromptu feedback, feedback from exit focus groups and overall experiences and lessons learned. 
Cons ideration for making substantial changes during the trial would occur if major issues were identified 
that seriously jeopardize recruitment, attendance, retention, or data collection efforts . Otherwise, we will 
carefully track issues during each wave, making minor changes to improve perform ance, and solicit 
feedback about i ssues during exit focus groups . If recruitment, attendance,  and retention are not hugely 
jeopardized, the team may wait to make  substantive changes until after all the feasibility, patient 
acceptability, and exit focus group data are analyzed.  
 11 DATA COLLECTION ASSSEMENT SCHEDULE 
 
The data collection assessm ent schedule is shown in Table 2.  
 
11.1 PRO Assessments  
In both conditions, P RO survey data will be collected directly from patients during the following assessment 
periods:  
 
T1: Pre -intervention (time period: Within 30 days prior to start of 1
st intervention session);  
T2: After the 5th intervention  session (time period: Within 21 days after the 5th session);  
T3: After the 10th intervention session (Time period: Within 21 days after the 10th session); and  
T4: At post -intervention after the 14th session (Time period: within  14 days after the 14th session).  
 
11.2 Salivary Cortisol  
Saliva samples will be collected from participants in both conditions pre- intervention and post -intervention 
as described below. Pre- intervention time period is within 7 days prior to 1st intervention session. Post -
intervention time period is within 7 days after final 14th intervention session.  
 
11.3 VC-CBCS Process Assessments  
In participants assigned to the VC -CBCS condition, they will submit self -report data directly into REDCap 
after each of the 14 intervention sessions to collect process data. Data collected will include Patient 
Satisfaction/Acceptability Ratings; S -M-A-R-T (specific, measurable, action -oriented, realistic, and time-
based) goals; Ratings of Importance, Motivation and Self -Confidence related to each SMART goal.  
 
VC-CBCS Study protocol v 7.0—16Nov 2021  
 Table 2: Data Collection Schedule  
 
 
12 MEASURES TO EVALUATE FOUR SPECIFIC AIMS  
 
12.1 Study and Intervention Feasibility  (Aims #1, #2)  
To address specific aims #1 and #2, several feasibility measures will be collected  from all participants . To 
evaluate the feasibility of conducting a larger RCT of the VC -CBCS, we will collect data on the proporti on of 
patients who are approached/contacted by study staff (Napproached) vs. consented (Nconsented) vs. 
randomized/ enrolled ( NR/E) vs. retained (Nretained). Feasibility of data collection, EHR extraction of clinica l 
data, and frequency and patterns of missing data on various outcomes will be evaluated (i.e., PROs, 
process/intermediate outcomes, salivary samples, clinical/disease outcomes). To evaluate the feasibility of 
delivering the intervention via video technology , we will collect feasibility data o n the proportion of sessions 
attended by VC -CBCS participants , have patients complete a telehealth satisfaction survey,  and track the 
frequency and nature of technical, logistical, and  participant problems.  
 
12.2 Patient Satisfaction (Aim #3)  
To address s pecific aim #3, several measures of patient satisfaction will be collected. VC -CBCS patients 
will complete a Patient Acceptability/Satisfaction survey after each of the 14 sessions.6 They will complete 
a survey on satisfaction with therapist and group dynamics midway through and at end of the 
intervention.6,99,110,111 Reasons for drop out and attrition will be evaluated in both conditions. Exit group 
interviews will be conducted with each VC -CBCS cohort after the intervention ends and will be audio-
recorded. The audio recording will be stored on a secure network server  housed by UNC . The qualitative 
data will be analyzed to understand likes/dislikes, pros/cons, and solicit feedback on optimizing the intervention (e.g., num ber and duration of sessions, modules, relaxation skills, structure, group format, data 
collection) . For the Patient Acceptability/Satisfaction Survey , items are scored on a scale from 1= not at all 
to 5=extremely. Data across all patients and  all sessions  will be averaged into a Total Patient Satisfaction Table 2  0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 
1. Study Feasibility                 
# approached  to consented  X               
# consented to eligible  X               
# eligible to enrolled /randomized  X               
# enrolled /randomized  to retained  X              X 
Randomization  X               
Session Attendance   X X X X X X X X X X X X X X 
Data Collection  X X X X X X X X X X X X X X X 
Technology/Logistical Problems  X X X X X X X X X X X X X X X 
2. Patient Satisfaction                 
Patient Acceptability   X X X X X X X X X X X X X X 
Reasons for drop out   X X X X X X X X X X X X X X 
Group Dynamic Survey       X         X 
Exit Focus Groups                X 
3. Protocol Fidelity                 
Facilitator  Adherence   X X X X X X X X X X X X X X 
      Facilitator  Competence   X X X X X X X X X X X X X X 
4. Patient Features                 
NINR sociodemographic data  X               
Screening information  X              X 
Clinical / lab data   X              X 
5. Intervention Targets  X X X X X X X X X X X X X X X 
6a. Intermediate Outcomes/ Mediators  X     X     X    X 
6b. Salivary Cortisol  X              X 
7a. PROs  X     X     X    X 
7b. Liver enzymes / clinical data  X              X 
VC-CBCS Study protocol v 7.0—16Nov 2021  
 score that could range from 1 to 5 with higher scores indicating greater satisfaction.  One secondary 
outcome is the overall Patient Acceptability/Satisfaction survey mean score from all patients over all 14 
sessions.  
 
12.3 Patient -Reported Outcome Measures  (Aim #4)  
To address specific aim #4, several PRO measures will be collected to evaluate primary, secondary and 
exploratory outcomes  to examine the temporal associations and strength of associations among variables 
in the preliminary conceptual  described in Figure 1.  PROs will be collected from all participants at four PRO 
time points (T1- T4). Collection of PRO data serves several preparatory functions for the efficacy trial 
including mak ing final selection of PROs, contributing to sample size calculations, and exploring 
preliminary relationships with other variables in the causal pathway.  
 
13 PRIMARY FEASIBILITY  OUTCOME MEASURES  
 
13.1 Percentage of Patients Consented Versus Approached  
13.2 Percentage of Participants Consented Versus Randomized  
13.3 Percentage of Standard of Care Condition Participants Retained vs Enrolled 
13.4 Percentage of VC -CBCS Intervention Condition Participants Retained vs Enrolled 
13.5 Percentage of Surveys Compl eted by Participants Who Completed the Study  
 
14 PRIMARY PATIENT -REPORTED OUTCOME MEASURES  
Several of the NIH Patient -Reported Outcomes Measurement System (PROMIS ®) short forms will be used 
to measure primary outcomes such as health status, mental health symptoms, and physical health  
symptoms . We have found the PROMIS ® surveys to have good psychometrics in HCV patients.124 The 
primary  patient -reported outcomes will be the mean T- scores  at T1 (Base line) and T4 (end of intervention):  
14.1 PROMIS Global Health Status Mental Health Mean T- Score 
14.2 PROMIS Global Health Status Physical Health Mean T -Score  
14.3 PROMIS Depression Mean T- score  
14.4 PROMIS Anger Mean T- score  
14.5 PROMIS Anxiety Mean T-score  
14.6 PROMIS Fatigue Mean T- score  
14.7 PROMIS Sleep Disturbance Mean T -score  
14.8 PROMIS Pain Interference Mean T -score  
 
15 SECONDARY PATIENT -REPORTED OUTCOME MEASURES 
 
15.1 The Perceived Stress Scale  Mean Score (PSS) measure s perceived stress in all participants at four 
PRO time points (T1- T4) and cover s 30 days prior to assessment.115 The PSS is a widely used survey to 
measure stress perception. The scale includes 10 items, rated using a 5 -point scale, from 0 (never) to 4 
(very often) where patients report the frequency of stress symptoms in the past month. Higher PSS scores 
reflect higher subjective stress.   
15.2 Sleep Behaviors  
15.2.1 Pittsburgh Sleep Quality Index (PSQI)  measures sleep behaviors and issues.117 All participants 
complete this measure at PRO time points T1 and T4 that cover s 30 days prior to assessment. "During 
the past month, how would you rate your sleep quality overall?" The res ponse set range s from a 
minimum of 0 (Very Good) to a maximum of 3 (Very Bad). Higher mean scores indicate worse sleep 
quality.  
15.2.2 Pittsburgh Sleep Quality Index (PSQI) Sleep Efficiency Composite Mean Score. Items 1, 3 and 4 
from the Pittsburgh Sleep Q uality Index (PSQI) were used to create a Sleep Efficiency composite 
score. All participants completed this measure at T1 and T4 that covered 30 days prior to assessment. 
The sleep efficiency score = (# hours slept/# hours in bed) X 100% .The sleep efficiency composite 
VC-CBCS Study protocol v 7.0—16Nov 2021  
 score ranged from: 0 = >85% efficiency,1 = 75- 84% efficiency, 2= 65- 74% efficiency, and 3= <65%. 
Lower scores indicate better sleep efficiency.  
15.2.3 Healthy Sleep Behaviors Mean Score.  One item "In the last month, how often did you engage in 
healthy sleep behaviors before bedtime?" evaluated healthy sleep behaviors. All participants completed 
this measure at T1 and T4. The response set ranged from 0 (not at all) to 4 (almost every night). Higher 
scores indicated better sleep behavior s. 
15.3 Medication Adherence Visual Analog Scales evaluate medication adherence for up to five daily 
medications for multiple comorbidities in the past 7 days in participants who were prescribed medications at baseline. Participants report the average adhe rence over the course of 7 days for each medication on a 
scale from 0% to 100% adherence for each medication.  
15.4 Coping Skills Confidence Mean Score: Items from the Measure of Current Status (MOCS) -Part A 
will measure patient confidence in performing multiple skills including stress awareness, relaxation, 
assertiveness, and coping skills.
114 The Measure of Current Status (MOCS) -Part A will measure patient 
confidence in performing multiple skills including stress awareness, relaxation, assertiveness, and coping 
skills. The scale contains 13 items rated on a scale from 0 = I cannot do this at all to 4 = I can do this 
extremely well. A Total Coping Skills score is created by taking the average of the 13 items where the Total 
Coping Skill score can range from 0 to 4.   
15.5. Alcohol and Drug Use:  Items from t he Substance Abuse and Mental Illness Symptoms Screener 
(SAMISS) Survey evaluate self -reported alcohol use (3 items) , non-prescription street drug use (1 item) , 
and prescription drug misuse  (1 item) in all participants. Individual scores could range from 0 to 4, with 
higher reported mean scores indicating higher consumption.  
15.6 Behavioral Risk Factor Surveillance System (BRFSS)116 items measure health behaviors such as 
exercise; fruit, vegetable, added sugar and sweet beverage consumption; meals prepared at home  in all 
participants at T1 (baseline) and T4 (Week 14) and will cover 30 days prior to assessment.  BRFSS items 
were used to measure the following secondary outcomes:  
15.6.1 Percentage of Participants Who Improved Fruit Consumption by One or More Categories  
15.6.2 Percentage of Participants Who Improved Vegetable Consumption by One or More Categories  
15.6.3 Percentage of Participants Who Complete Moderate Activity for at Least 10 Minutes at a Time 
15.6.4 Mean Number of Minutes of Moderate Activity Per Week  
15.6.5 Percentage of Participants Who Complete Vigorous Activity for at Least 10 Minutes at a Time 
15.6.6 Mean Number of Minutes of Vigorous Activity Per Week  
15.6.7 Mean Time Spent Sitting on the Weekdays  
15.6.8 Mean Time Spent Sitting on the Weekends  
15.6.9 Percentage of Participants Who Reduced Regular Soda Intake by One or More Categories  
15.6.10 Percentage of Participants Who Reduced Diet Soda Intake by One or More Categories  
15.6.11 Percentage of Participants Who Reduced Meals from  Fast Food Rest aurants by One or More 
Categories  
15.6.12 Percentage of Participants Who Increased Dinners Prepared at Home by 1 or More Days  
 
15.7 Participant Satisfaction With VC -CBCS Intervention Mean Score: After each VC -CBCS 
intervention session, participants complete a 14- item acceptability/satisfaction survey about their 
impressions with the current intervention session. Items are scored on a scale from 1= not at all to 
5=extremely useful. Data across all VC -CBCS participants and all intervention sessions are averaged into 
a Total Patient Satisfaction score that could range from a minimum of 1 to a maximum of 5 with higher scores indicating greater satisfaction.  
 
15.8 Weight Changes . Change in raw weight, percent weight change, and BMI evaluated among those 
who had pre -intervention BMI > 24.9 (overweight and above) from T1 to T4.  
 
16 SECONDARY CLINICAL OUTCOMES  
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) are  extracted from all participants 
electronic health records (EHRs)  who had already achieved viral cure at baseline and who were not on 
HCV treatment at baselin e in order  to determine feasibility of extracting these data from the medical record 
VC-CBCS Study protocol v 7.0—16Nov 2021  
 and explore pre and post intervention mean scores in these two markers of liver inflammation. Mean AST 
and ALT levels are  compared in both females and males.  
 
17 EXPLORATORY PATIENT -REPORTED OUTCOME  MEASURE  
 
17.1 Satisfaction with Telehealth Session Mean Score. After session 1 and session 14 , participants  
complete a 15 -item acceptability/satisfaction survey about their  satisfaction with using telehealth sessions. 
Items are scored on a scale from 1= strongly disagree to 5= strongly agree. The average Total Telehealth 
Satisfaction score is analyzed from session 1 and session 10, which could range from 1 to 5 with higher 
scores indicating greater satisfaction.  
 
18 EXPLORATORY STRESS BIOMARKER OUTCOME  
Participants in both conditions collect saliva samples at baseline (T1) and post -treatment (T4). Cortisol 
secretions follow a diurnal pattern, but physiological and psychological stress disrupt normal rhythms, 
dysregulat e the sympathetic nervous system and HPA axis and are associated with poor health. 
Conversely, stress management skills regulate cortisol patterns.32,92,118 -120 Participants will be given two 
salivary collection kits to provide salivary samples pre - and post -intervention. Participants will provide 
salivary samples four times: immediately upon wakening, 30 minutes after awakening, in the late afternoon, 
and at bedtime. Research staff will contact patients the day prior to collection to remind them of the 
protocol. Samples will be stored in participants’ home refrigerators within 30 minutes of collection and 
mailed to UNC in pre -paid gel wrap mailers. Samples will b e stored at −80°C until assayed. Collection and 
storage methods have been validated.121 Saliva samples will be stored de- identified using subject ID 
number only. Mean log 10 cortisol as a diurnal function of time of day and summary values such as the area 
under the curve (AUC), AUC minus ground will be compared from T1 to T4. Lower cortisol levels indicate a 
lower level of stress .  
 
19 INTERVENTION TARGETS  
VC-CBCS  participants will complete a weekly Post -Intervention Form after each of 14 sessions directly i nto 
REDCap on their iPad or home technology.  
 
19.1 SMART Goals related to health changes, stress management, and cognitive- behavioral skills. After 
each new session, each patient  will describe at least one new SMART goal related to the session topic 
such that after session one, they describe one goal…after  session 14, they describe 14 goals, one per 
topic.  
 
19.2 For each SMART goal, patients will rate the Importance/Relevance of the particular goal, their 
Motivation to achieve the goal, and their Self -Efficacy  to achieve the particular goal. The three ratings will 
be on a Numeric Rating Scale ranging from 0% to 100%. 
 
20 PATIENT SOCIODEMOGRAPHICS  
At baseline ( T1), all participants will self -report the following NINR data elements: age, sex, race, ethnicity, 
marital status, income, education level, employment status, caregiver type, household member total count, 
and health comorbidities.112-114 History of psychiatric, alcohol  and substanc e use issues w ill be obtained 
during the screening process  and transferred to the research database for enrolled patients . All data will be 
cross- validated with data reviewed in patients’ EHRs.  
 
21 PROTOCOL FIDELITY  
To examine the Group Facilitator’s competency and fidelity to the intervention protocol and 14 modules, we 
will utilized two observer -rating forms to evaluate Facilitator Adherence and Facilitator Competency  to 
manage group dynamics. A research staff member will observe VC -CBCS sessions and complete the 
observer -rating Facilitator Adherence form, rating the proportion of sections completed on scale of 0- 100%. 
The staff member will also complete the Facilitator Competency observer -rating form, a 14- item Likert 
VC-CBCS Study protocol v 7.0—16Nov 2021  
 scale (1=not at all; 4=extremely).  The Facilitator will not have access to these ratings until completion of 
each cohort.  
 
22 ELECTRONIC DATA CAPTURE AND SECURE STORAGE  
 
Data will be directly entered and stored in the web- based research electronic data capture system, 
REDCap ( https://projectredcap.org/ ). The REDCap system is a secure, HIPAA -compliant web -based 
application to support distributed data collection governed by standard University, School of Medicine, and 
Federal information security policies and standards . The REDCap application is hosted and monitored on a 
secure server located within the UNC CTSA -funded NC TraCS Insti tute’s Bioinformatics Core. Access to 
the REDCap database for this study will be restricted to authorized research team members as needed to 
perform their job functions. Research staff who access the REDCap system will use a unique user ID 
provided by the Bioinformatics Core. Research staff will enter EHR data into clinical forms on REDCap. 
Each time research staff access REDCap, a unique electronic signature (login) is required, and REDCap 
maintains an audit trail of all activity. Participants will be give n the choice of providing PRO data (a) directly 
into REDCap from a weblink set up on their iPad, (b) from an automated email from the REDCap system that contains a URL link to the survey or (c) through phone- delivered surveys with study staff who enter 
responses directly into REDCap. Each REDCap link is unique to each subject and each assessment 
period. Patients will be sent electronic reminders from REDCap to approved email addresses when PRO data entry is needed.   
 
For each consented patient, their consent documents will be uploaded and stored in REDCap. Hard copy 
consent documents will be stored in a secure location.  
 
While the research data will be stored in REDC ap, other study materials (e.g., SAE/AE forms, 
reimbursements, audio- video recordings)  will be securely stored on VPN - and password protected CGIBD 
secure server in a study folder. The server and study folders are maintained and monitored by UNC SOM 
ITS. ITS will provide access only to staff working on this project. No study -related documents containing 
patient PHI or identifiers will reside on desktop or laptop computers.   
 
23 DATA ANALYSIS  
 
23.1 Statistical Analysis Overview  
The analysis strategies are designed to inform the feasibility and planning of a subsequent efficacy RCT. 
No hypothesis tests will be conducted. Statistical estimates will be reported with 95% confidence intervals 
(CIs)  or standard deviations . Collectively, the  results of this preparatory study will allow us to formulate 
reasonable expectations for the subsequent RCT. A publicly available PROMIS® scoring system is available for computing PROMIS T- scores. Statistical computations will be performed in SAS software 
(SAS Institute, Cary, NC).  
 
23.2 Aim 1: Feasibility of conducting a RCT 
Frequencies will be tabulated for the following: patients approached/called, consented, 
randomized/ enrolled, retained, completed surveys , and salivary cortisol samples. We will examine reasons 
for refusal, causes of dropout , session attendance, causes and patterns of missing data, and technical and 
logistical difficulties with delivering the intervention via VC. We anticipate that >50% of a pproached/called 
patients will consent; >75% of consented patients will be randomized and enroll ; >80% will be retained; and 
>90% of PRO and cortisol data will be collected.  
 
23.3. Aim 2: Feasibility of intervention delivery  
Technical and logistical issues  with VC technology, internet, and software will be recorded. Descriptive 
methods will summarize the proportion of sessions attended. We anticipate >75% of VC -CBCS participants 
will attend >75% of sessions.  
 
VC-CBCS Study protocol v 7.0—16Nov 2021  
 23.4 Aim 3: Patient satisfaction and acceptabili ty 
Qualitative data from each exit focus groups will be obtained to help improve the structure and content of 
the future VC-CBCS and study methods. The P atient Acceptability /Satisfaction  survey will be analyzed as 
an average for the 14 sessions.6 Items on the group dynamics  survey will be evaluated at both  time 
points.6,99,110,111  Reasons for drop out  will be evaluated in both conditions. We anticipate that patients will 
find the VC -CBCS highly acceptable and useful, as m easured by the Patient Acceptability s urvey and 
information provided during the exit focus groups. If 19 of the 24 VC -CBCS participants find the 
intervention acceptable ( overall score ≥3.5 out of 5.0), the point and interval estimate will be 79% [95% CI: 
61, 100].  
 
23.5 Aim 4:  Explore changes in patient outcomes, mediators and intervention targets, as well as 
temporal associations and strength of associations among variables in a preliminary conceptual 
model, to inform a future efficacy trial  
For each outcome measured before, during and after the intervention, we will obtain estimates of specific 
mean changes, treatment effects, standard deviations, serial correlations, corresponding confidence 
intervals indicating levels of precision or  standardized ef fect size estimates (Cohen’s d) of change. We 
anticipate that mean changes will favor the VC -CBCS intervention relative to SC.  
 
Various exploratory methods may be used to fully examine the data and generate hypotheses to be 
evaluated in a future RCT. We may explore the weekly repeated measures for intervention targets and 
potential mediators /intermediate outcomes  to identify targets rated as strongest by patients, and to identify 
the timing and magnitude of changes in mediators /intermediate outcomes  during the VC -CBCS. To better 
understand potential causal pathways and refine the conceptual model , we may explore temporal 
correlations among targets, mediators (intermediate/secondary  outcomes) and primary patient -reported 
and clinical  outcomes. For example, w e may explore associations of mediators with intervention- induced 
changes in health status, physical and mental symptoms, salivary cortisol, ALT  and AST. We will estimate 
mean log 10 cortisol as a diurnal function of time of day and compute summary values s uch as the area 
under the curve (AUC), AUC minus ground, and cortisol awakening.  
 24 STUDY CONDUCT  
 
This study will be conducted in accordance wi th federal  and institutional guidelines  
(https://www.hhs.gov/ohrp/regulations -and-policy/regulations/finalized- revisions -common- rule/index.html
;  
(https://www.hhs.gov/ohrp/regulations -and-policy/regulations/finalized- revisions -common- rule/index.html ) 
and relevant Good Clinical Practice (GCP) Guidelines described by the International Conference on 
Harmonization (ICH). The study will be conducted in compliance with this version of the study protocol. The 
protocol and any amendments will receive UNC Institutional Review Board (IRB) approval prior to initiation 
of the st udy. Study personnel involved in conducting this study will be qualified by education, training, and 
experience to perform their respective tasks.  
 
We will apply all standard protections of patient confidentiality and data integrity during this study. Consent 
forms will be uploaded to REDCap and hard copies stored in a secure, locked location. All research data 
will be stored on a secure electronic server, behind a firewall at UNC, maintained and monitored by the 
UNC SOM ITS. Study documents will be stored in locked and secure file cabinets  and on the CGIBD 
secure server in a folder accessible only to study staff. Audio- video files of the intervention will be uploaded 
to the CGIBD secure server to the private research folder.   
 
25 DATABASE RETENTION  
 The REDC ap database and all study -related materials w ill be maintained until all data are published and up 
to 5-7 years after the end of the study at UNC by the PI in collaboration with the NC TraCS  Institute and 
SOM ITS . Hard copy data will be securely stored on the secure server and in locked cabinets. Acces s to 
electronic folders and REDC ap will be terminated for s taff no  longer working on the project. D ata initially 
stored on screened patients who were not enrolled w ill be deleted at the end of the study. If datasets are 
exported for analysis, no identifiers or contact information will be exported.  
 
VC-CBCS Study protocol v 7.0—16Nov 2021  
 26 DATA AND SA FETY AND MONITORING PLAN  
 
This study has a full DSMP that has been reviewed and approved by the NIH National Institute of Nursing 
Research (NINR)   and is in accordance with the Policy of the N INR for Data and Safety Monitoring of 
Extramural Clinical Trials . Available in supplementary attachment. Study staff will adhere the guidelines in 
the DSMP.  
 
26.1 Procedures for Adverse Events (from DSMP v2.0 - 27Sept2019 ) 
In brief, we will identify, review, and report study -related serious adverse events (SAEs) according to UNC 
regulatory guidelines and OHRP Guidance on Reviewing and Reporting Unanticipated Problems Involving 
Risks to Subjects or Others and Adverse Events. The UNC IRB Standard Operating Procedures (dated: 
6/2/2017) defines a reportable serious adverse events (SAE) as any event temporally associated with the 
subject’s participation in research that meets any of the following criteria: 1) results in death, 2) is life 
threatening, 3) requires inpatient hospitalization or prolongation of existing hospitaliz ation, 4) results in 
persistent or significant disability/incapacity, 5) results in congenital anomaly/birth defect, or 6) any other 
adverse event that, based on appropriate medical judgement, may jeopardize the subject’s health and may 
require medical or surgical intervention to prevent one of the outcomes listed above (UNC SOP 1401: 
3.2.2.1.1). These SAEs will be reported immediately to the PI and Dr. Lechner, the Independent Safety Monitor (ISM), within 48 hours of notification. The PI and ISM will review the SAE and determine if the SAE 
is partially or fully related to study participation. (Note: We do not anticipate any study -related SAEs or AEs 
based on prior experience conducting these interventions and as this is a minimal risk behavioral 
intervention including no drugs, devices or procedures). Based on SAE review and ISM, the SAE 
outcome/conclusion will be recorded with study records. If the SAE is determined to be study -related, an 
ISM summary will be reported to the UNC IRB within 7 calendar days. If not study -related, it will be tracked 
but not reported. Unanticipated study -related AEs or problems will be reported within 14 days to the IRB. 
We will record SAEs and unanticipated study -related AEs in a regulatory binder. The NINR Program Officer 
will be notified of study -related SAEs or study -related unanticipated AEs within one month of reporting the 
event to the UNC IRB (per OHRP Guidance recommendations).  
 
The target population has a higher prevalence of medical, psychiatric, and substance use dis orders and 
conditions. Therefore, we anticipate learning about non -study related patient issues related to liver, 
cirrhosis, psychiatric, or substance use issues due to the natural history or these disorders and higher risk 
of these disorders in the target  population. Under this protocol, the PI and ISM will not report non -study 
related events such as inpatient hospitalizations for medical conditions or symptoms (e.g., complaints of 
fatigue, nausea, pain) to the IRB or sponsor, although reports of these events will be tracked in a regulator y 
binder. We will follow a SOP to handle non -study related medical or psychiatric issues.   
 
Dr. Evon will provide oversight and direct patient care commensurate with good clinical practice as a 
clinical psychologist and member of the UNC Liver Program. We do not anticipate any events that would 
halt accrual. If an event should occur, it would be discussed with ISM, staff and telemental health 
consultants. A review of eligibility criteria, patient monitoring, assessments, or the intervention may occur 
but is unlikely to halt accrual.  
 
27 RESEARCH TEAM  
NAME  DEPARTMENT NAME  ROLE  
Donna Evon  UNC Depar tment of Medicine  Principal Investigator  
Michael Fried  UNC Department of Medicine  Co-Investigator  
Susan Girdler  UNC Department of Psychiatry  Co-Investigator  
Dawn Harrison  UNC Gastroenterology and Hepatology  Co-Investigator  
Deborah Tate  UNC Department of Health Behavior and 
Department of Nutrition  Co-Investigator  
Chip Bailey  Duke University School of Nursing  Co-Investigator  
Suzanne Lechner  n/a Independent Contractor  Independent Safety Monitor  
VC-CBCS Study protocol v 7.0—16Nov 2021  
 Cathryn Mainville  n/a Etheridge Private Practice  Group Facilitator  
Leslie Morland  University of California, San Diego  
Department of Psychiatry  
Director, San Diego Regional Telemental 
Health Program, San Diego VA Health Care 
System  Telemental health  
Consultant  
Jeremy Simpson  UNC School of Medicine  
Information Technology Security (ITS)  AV Support  Engineer  
 
Paul Stewart  UNC Department of Biostatistics  Biostatistician  
Ashley Arrington  NC Tr aCS Institute, RCMU  Project Manager  
Taylor Caron  Center for Gastrointestinal Biology and 
Disease  Research Coordinator  
Ginny Sharpless  Center for Gastrointestinal Biology and 
Disease  Data Management 
Consultant  
28 GLOSSARY OF TERMS 
 
A1C – Hem oglobin A1C  
AE- adverse event  
ALT - alanine aminotransferase  
AST - aspartate aminotransferase  
BRFSS - Behavioral Risk Factor Surveillance System  
CB – cognitive behavioral  
CBCS - cognitive behavioral coping skills  
CBSM – cognitive behavioral stress management  
CBT – cognitive behavioral t reatment  
CGIBD - Center for Gastrointestinal Biology and Diseases  
CTSA – clinical and translational science awards  
CONSORT – Consolidated Standards for Reporting of Trials  
DSMP – data safety monitoring plan  
HCV - hepatitis C virus  
HCV -PEG – Hepatitis C Virus Patient Engagement Group  
HCV RNA –  HCV RNA PCR test  
IMB - informational -motivation- behavioral skills  
IRB – Internal Review Board  
MOCS - Measure of Current Status -Part A  
NC TraCS - North Carolina Translational & Clinical Sciences Institute  
NIH- National Institutes of Health  
NINR – National Institute of Nursing Research  
PRO - patient -reported outcomes  
PROMIS - Patient Reported Outcomes Measurement System  
PROP UP –  patient reported outcomes project of HCV -TARGET  
PSS – perceived stress scale 
HRQOL - health -related quality of life  
RCT - randomized controlled trial  
REDCap - research electronic data capture system  
SAE – serious adverse event  
SAMISS - Substance Abuse and Mental Illness Brief Symptom Screener  
SC – standard of care 
SM – stress management  
VC - videoconference  
 
 
 
VC-CBCS Study protocol v 7.0—16Nov 2021  
 29 REFERENCES  
  
1. Bleich SN, Sherrod C, Chiang A, et al. Systematic Review of Programs Treating High- Need and High-
Cost People With Multiple Chronic Diseases or Disabilities in the United States, 2008- 2014. Preventing 
chronic disease.  2015;12:E197.  
2. Yanez B, McGinty HL, Mohr DC, et al. Feasibility, acceptability, and preliminary efficacy of a 
technology -assisted psychosocial intervention for racially diverse men with advanced prostate cancer. 
Cancer. 2015;121(24):4407- 4415.  
3. Kinner  EM, Armer JS, McGregor BA, et al. Internet- Based Group Intervention for Ovarian Cancer 
Survivors: Feasibility and Preliminary Results. JMIR cancer. 2018;4(1):e1.  
4. Sansom -Daly UM, Wakefield CE, Bryant RA, et al. Online group -based cognitive- behavioural t herapy 
for adolescents and young adults after cancer treatment: a multicenter randomised controlled trial of 
Recapture Life- AYA. BMC.Cancer. 2012;12:339. doi: 10.1186/1471- 2407 -12-339.:339- 312. 
5. Marziali E. E -health program for patients with chronic disease. Telemed.J.E.Health. 2009;15(2):176-
181. 
6. Evon DM, Golin CE, Ruffin R, Fried MW. Development and pilot -testing of a cognitive behavioral coping 
skills group intervention for patients with chronic hepatitis C. Contemporary Clinical Trials 
Communications. 2017;6:85- 96. 
7. Morland LA, Greene CJ, Rosen CS, et al. Telemedicine for anger management therapy in a rural 
population of combat veterans with posttraumatic stress disorder: a randomized noninferiority trial. 
J.Clin.Psychiatry. 2010;71(7):855- 863. 
8. Morland LA, Mackintosh MA, Greene CJ, et al. Cognitive processing therapy for posttraumatic stress disorder delivered to rural veterans via telemental health: a randomized noninferiority clinical trial. The 
Journal of clinical psychiatry. 2014;75(5):470 -476. 
9. Khatri N, Marziali E, Tchernikov I, Shepherd N. Comparing telehealth- based and clinic -based group 
cognitive behavioral therapy for adults with depression and anxiety: a pilot study. Clinical interventions 
in aging. 2014;9:765 -770. 
10. Marziali E, Ga rcia LJ. Dementia caregivers' responses to 2 Internet -based intervention programs. 
American journal of Alzheimer's disease and other dementias. 2011;26(1):36- 43. 
11. Denniston MM, Jiles RB, Drobeniuc J, et al. Chronic hepatitis C virus infection in the Uni ted States, 
National Health and Nutrition Examination Survey 2003 to 2010. Ann Intern Med. 2014;160(5):293 -300. 
12. Edlin BR, Eckhardt BJ, Shu MA, Holmberg SD, Swan T. Toward a more accurate estimate of the 
prevalence of hepatitis C in the United States. H epatology. 2015;62(5):1353- 1363.  
13. Ferri C, Ramos -Casals M, Zignego AL, et al. International diagnostic guidelines for patients with HCV -
related extrahepatic manifestations. A multidisciplinary expert statement. Autoimmunity reviews. 
2016;15(12):1145 -1160.  
14. Huckans M, Fuller BE, Olavarria H, et al. Multi -analyte profile analysis of plasma immune proteins: 
altered expression of peripheral immune factors is associated with neuropsychiatric symptom severity in adults with and without chronic hepatitis C v irus infection. Brain and behavior. 2014;4(2):123- 142. 
15. Forton DM, Allsop JM, Cox IJ, et al. A review of cognitive impairment and cerebral metabolite abnormalities in patients with hepatitis C infection. AIDS. 2005;19 Suppl 3:S53- S63. 
16. Lang CA, Conrad S, Garrett L, et al. Symptom prevalence and clustering of symptoms in people living 
with chronic hepatitis C infection. J.Pain Symptom.Manage. 2006;31(4):335- 344. 
17. Younossi Z, Kallman J, Kincaid J. The effects of HCV infection and management on health- related 
quality of life. Hepatology. 2007;45(3):806 -816. 
18. Basseri B, Yamini D, Chee G, Enayati PD, Tran T, Poordad F. Comorbidities associated with the 
increasing burden of hepatitis C infection. Liver international : official journal of the International 
Association for the Study of the Liver. 2010;30(7):1012- 1018.  
19. Carlson MD, Hilsabeck RC, Barakat F, Perry W. Role of Sleep Disturbance in Chronic Hepatitis C 
Infection. Curr Hepat Rep. 2010;9(1):25 -29. 
20. Lovejoy TI, Dobscha SK, Cavanagh R, Turk DC, Morasco BJ. Chronic pain treatment and health 
service utilization of veterans with hepatitis C virus infection. Pain Med. 2012;13(11):1407 -1416.  
21. Kallman J, O'Neil MM, Larive B, Boparai N, Calabrese L, Younos si ZM. Fatigue and health- related 
quality of life (HRQL) in chronic hepatitis C virus infection. Dig.Dis.Sci. 2007;52(10):2531 -2539.  
VC-CBCS Study protocol v 7.0—16Nov 2021  
 22. Spiegel BM, Younossi ZM, Hays RD, Revicki D, Robbins S, Kanwal F. Impact of hepatitis C on health 
related quality of li fe: a systematic review and quantitative assessment. Hepatology. 2005;41(4):790-
800. 
23. Jakobsen JC, Nielsen EE, Feinberg J, et al. Direct -acting antivirals for chronic hepatitis C. Cochrane 
Database Syst Rev. 2017;6:Cd012143.  
24. Jacobson IM, Lim JK, Fri ed MW. American Gastroenterological Association Institute Clinical Practice 
Update- Expert Review: Care of Patients Who Have Achieved a Sustained Virologic Response After 
Antiviral Therapy for Chronic Hepatitis C Infection. Gastroenterology. 2017;152(6):1578 -1587.  
25. Evon DM, Stewart PW, Sarkar S, et al. Amelioration of HCV -associated symptoms after achieving viral 
cure from chronic hepatitis C with direct acting antivirals: A large real world cohort study  Under 
Review.  
26. Wilson MP, Castillo EM, Batey AM , Sapyta J, Aronson S. Hepatitis C and depressive symptoms: 
psychological and social factors matter more than liver injury. Int.J.Psychiatry Med. 2010;40(2):199-215. 
27. Prevention CfDCa. Establishing a Holistic Framework to Reduce Inequities in HIV, Viral  Hepatitis, 
STDs, Tuberculosis in the United States. U.S. Department of Health and Human Services. October 
2010.  
28. Loprinzi PD, VanWagner LB. Survival effects of physical activity on mortality among persons with liver 
disease. Preventive medicine reports . 2016;3:132 -134. 
29. Nobili V, Carter -Kent C, Feldstein AE. The role of lifestyle changes in the management of chronic liver 
disease. BMC.Med. 2011;9:70.:70.  
30. Andersen BL, Farrar WB, Golden- Kreutz DM, et al. Psychological, behavioral, and immune change s 
after a psychological intervention: a clinical trial. Journal of clinical oncology : official journal of the 
American Society of Clinical Oncology. 2004;22(17):3570 -3580.  
31. Antoni MH. Stress management effects on psychological, endocrinological, and im mune functioning in 
men with HIV infection: empirical support for a psychoneuroimmunological model. Stress. 
2003;6(3):173 -188. 
32. Antoni MH, Cruess DG, Klimas N, et al. Increases in a marker of immune system reconstitution are 
predated by decreases in 24- h urinary cortisol output and depressed mood during a 10- week stress 
management intervention in symptomatic HIV -infected men. J Psychosom Res. 2005;58(1):3 -13. 
33. Antoni MH, Lutgendorf SK, Blomberg B, et al. Cognitive- behavioral stress management reverses  
anxiety -related leukocyte transcriptional dynamics. Biological psychiatry. 2012;71(4):366 -372. 
34. McGregor BA, Antoni MH, Boyers A, Alferi SM, Blomberg BB, Carver CS. Cognitive- behavioral stress 
management increases benefit finding and immune function am ong women with early -stage breast 
cancer. J.Psychosom.Res. 2004;56(1):1 -8. 
35. Given C, Given B, Rahbar M, et al. Effect of a cognitive behavioral intervention on reducing symptom 
severity during chemotherapy. J.Clin.Oncol. 2004;22(3):507 -516. 
36. Manber R , Edinger JD, Gress JL, San Pedro -Salcedo MG, Kuo TF, Kalista T. Cognitive behavioral 
therapy for insomnia enhances depression outcome in patients with comorbid major depressive disorder and insomnia. Sleep. 2008;31(4):489- 495. 
37. Keefe FJ, Caldwell DS. C ognitive behavioral control of arthritis pain. Med.Clin.North Am. 
1997;81(1):277 -290. 
38. Evon DM, Golin CE, Ruffin R, Ayres S, Fried MW. The Cognitive Behavioral Coping Skills (CBCS) 
Group Intervention for Patients with Chronic Hepatitis C: A Pilot Feasibility Randomized Controlled Trial 
2017.  
39. Arora S, Kalishman S, Thornton K, et al. Expanding access to hepatitis C virus treatment -Extension for 
Community Healthcare Outcomes (ECHO) project: Disruptive innovation in specialty care. Hepatology. 
2010.  
40. Hahm JS, Lee HL, Choi HS, Shimizu S. Telemedicine system using a high -speed network: past, 
present, and future. Gut and liver. 2009;3(4):247- 251. 
41. Schueller SM, Begale M, Penedo FJ, Mohr DC. Purple: a modular system for developing and deploying 
behavior al intervention technologies. Journal of medical Internet research. 2014;16(7):e181.  
42. Sansom -Daly UM, Wakefield CE, McGill BC, Wilson HL, Patterson P. Consensus Among International 
Ethical Guidelines for the Provision of Videoconferencing- Based Mental H ealth Treatments. JMIR 
mental health. 2016;3(2):e17.  
VC-CBCS Study protocol v 7.0—16Nov 2021  
 43. Somers TJ, Abernethy AP, Edmond SN, et al. A Pilot Study of a Mobile Health Pain Coping Skills 
Training Protocol for Patients With Persistent Cancer Pain. J Pain Symptom Manage. 2015;50(4):553-
558. 
44. Hall DL, Lattie EG, Milrad SF, et al. Telephone- administered versus live group cognitive behavioral 
stress management for adults with CFS. J Psychosom Res. 2017;93:41- 47. 
45. Morland LA, Greene CJ, Rosen CS, Kuhn E, Hoffman J, Sloan DM. Telehealth and eHealth 
interventions for posttraumatic stress disorder. Current opinion in psychology. 2017;14:102 -108. 
46. Morland LA, Hynes AK, Mackintosh MA, Resick PA, Chard KM. Group cognitive processing therapy 
delivered to veterans via telehealth: a pilot cohort. J Trauma Stress. 2011;24(4):465- 469. 
47. Huijbregts MP, McEwen S, Taylor D. Exploring the feasibility and efficacy of a telehealth stroke self -
management programme: a pilot study. Physiother.Can. 2009;61(4):210 -220. 
48. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: 
an update. Hepatology. 2009;49(4):1335 -1374.  
49. Koretz RL, Lin KW, Ioannidis JP, Lenzer J. Is widespread screening for hepatitis C justified? Bmj. 2015;350:g7809.  
50. Thein HH, Yi Q, Dore GJ, Krahn MD. Estimation of stage- specific fibrosis progression rates in chronic 
hepatitis C virus infection: a meta- analysis and meta- regression. Hepatology. 2008;48(2):418 -431. 
51. Younossi ZM. Hepatitis C Infection: A System ic Disease. Clinics in liver disease. 2017;21(3):449 -453. 
52. Petta S, Maida M, Macaluso FS, et al. Hepatitis C Virus Infection Is Associated With Increased Cardiovascular Mortality: A Meta -Analysis of Observational Studies. Gastroenterology. 
2016;150(1):145 -155.e144; quiz e115- 146. 
53. Evon DM, Stewart PW, Amador J, et al. A comprehensive assessment of patient reported symptom 
burden, medical comorbidities, and functional well being in patients initiating direct acting antiviral 
therapy for chronic hepatit is C: Results from a large US multi- center observational study. PLoS ONE. 
2018.  
54. Monaco S, Mariotto S, Ferrari S, et al. Hepatitis C virus -associated neurocognitive and neuropsychiatric 
disorders: Advances in 2015. World journal of gastroenterology : WJ G. 2015;21(42):11974 -11983.  
55. Conca P, Tarantino G. Hepatitis C virus lymphotropism and peculiar immunological phenotype: effects on natural history and antiviral therapy. World journal of gastroenterology : WJG. 2009;15(19):2305-
2308.  
56. Hayashi F, Mom oki C, Yuikawa M, et al. Nutritional status in relation to lifestyle in patients with 
compensated viral cirrhosis. World journal of gastroenterology : WJG. 2012;18(40):5759 -5770.  
57. Olson SH, Iyer S, Scott J, et al. Cancer history and other personal facto rs affect quality of life in patients 
with hepatitis C. Health and quality of life outcomes. 2005;3:39.  
58. Moon J, Kallman J, Winter P, et al. Disparities in activity level and nutrition between patients with 
chronic hepatitis C and blood donors. PM & R :  the journal of injury, function, and rehabilitation. 
2012;4(6):436 -441. 
59. Kolly P, Knopfli M, Dufour JF. Effect of smoking on survival of patients with hepatocellular carcinoma. Liver international : official journal of the International Association for  the Study of the Liver. 2017.  
60. Stepanova M, Younossi ZM. Economic Burden of Hepatitis C Infection. Clinics in liver disease. 2017;21(3):579 -594. 
61. Antoni MH, Lechner SC, Kazi A, et al. How stress management improves quality of life after treatment 
for breast cancer. J Consult Clin Psychol. 2006;74(6):1143- 1152.  
62. Antoni MH. Psychosocial intervention effects on adaptation, disease course and biobehavioral processes in cancer. Brain, behavior, and immunity. 2013;30 Suppl:S88- 98. 
63. Clevenger L, Schrepf A, Christensen D, et al. Sleep disturbance, cytokines, and fatigue in women with 
ovarian cancer. Brain, behavior, and immunity. 2012;26(7):1037 -1044.  
64. Lutgendorf SK, Andersen BL. Biobehavioral approaches to cancer progression and survival: 
Mechanisms  and interventions. The American psychologist. 2015;70(2):186- 197. 
65. Lutgendorf SK, Sood AK, Antoni MH. Host factors and cancer progression: biobehavioral signaling 
pathways and interventions. Journal of clinical oncology : official journal of the Americ an Society of 
Clinical Oncology. 2010;28(26):4094- 4099.  
66. Bisht B, Darling WG, Grossmann RE, et al. A multimodal intervention for patients with secondary 
progressive multiple sclerosis: feasibility and effect on fatigue. Journal of alternative and 
complementary medicine (New York, N.Y.). 2014;20(5):347- 355. 
VC-CBCS Study protocol v 7.0—16Nov 2021  
 67. Hickman IJ, Jonsson JR, Prins JB, et al. Modest weight loss and physical activity in overweight patients 
with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting 
insulin, and quality of life. Gut. 2004;53(3):413- 419. 
68. Rusu E, Jinga M, Enache G, et al. Effects of lifestyle changes including specific dietary intervention and physical activity in the management of patients with chronic hepatitis C --a randomized trial. Nutrition 
journal. 2013;12:119.  
69. Parmar P, Mackie D,  Varghese S, Cooper C. Use of telemedicine technologies in the management of 
infectious diseases: a review. Clinical infectious diseases : an official publication of the Infectious 
Diseases Society of America. 2015;60(7):1084- 1094.  
70. Saifu HN, Asch SM, G oetz MB, et al. Evaluation of human immunodeficiency virus and hepatitis C 
telemedicine clinics. Am.J.Manag.Care. 2012;18(4):207 -212. 
71. Groessl EJ, Sklar M, Cheung RC, Brau N, Ho SB. Increasing antiviral treatment through integrated hepatitis C care: a r andomized multicenter trial. Contemp.Clin.Trials. 2013;35(2):97- 107. 
72. Proeschold- Bell RJ, Evon DM, Makarushka C, et al. The Hepatitis C -Alcohol Reduction Treatment (Hep 
ART) intervention: Study protocol of a multi -center randomized controlled trial. . C ontemp.Clin.Trials. In 
Press.  
73. Richardson LK, Frueh BC, Grubaugh AL, Egede L, Elhai JD. Current Directions in Videoconferencing 
Tele- Mental Health Research. Clin.Psychol.(New York.). 2009;16(3):323- 338. 
74. Ertel AE, Kaiser TE, Abbott DE, Shah SA. Use o f video- based education and tele- health home 
monitoring after liver transplantation: Results of a novel pilot study. Surgery. 2016;160(4):869 -876. 
75. McCrossan B, Morgan G, Grant B, et al. A randomised trial of a remote home support programme for 
infants with major congenital heart disease. Heart. 2012;98(20):1523 -1528.  
76. Northouse LL, Mood DW, Schafenacker A, et al. Randomized clinical trial of a family intervention for 
prostate cancer patients and their spouses. Cancer. 2007;110(12):2809- 2818.  
77. Smith CE, Spaulding R, Piamjariyakul U, et al. mHealth Clinic Appointment P C Tablet: Implementation, 
Challenges and Solutions. Journal of mobile technology in medicine. 2015;4(2):21 -32. 
78. Gardner -Nix J, Backman S, Barbati J, Grummitt J. Evaluating distance education of a mindfulness -
based meditation programme for chronic pain m anagement. J.Telemed.Telecare. 2008;14(2):88- 92. 
79. Collie K, Kreshka MA, Ferrier S, et al. Videoconferencing for delivery of breast cancer support groups 
to women living in rural communities: a pilot study. Psychooncology. 2007;16(8):778- 782. 
80. Yalom I . The Theory and Practice of Group Psychotherapy.  New York: Basic Books; 2005.  
81. Somers TJ, Kelleher SA, Westbrook KW, et al. A Small Randomized Controlled Pilot Trial Comparing 
Mobile and Traditional Pain Coping Skills Training Protocols for Cancer Pati ents with Pain. Pain 
research and treatment. 2016;2016:2473629.  
82. Turner -McGrievy G, Tate D. Tweets, Apps, and Pods: Results of the 6 -month Mobile Pounds Off 
Digitally (Mobile POD) randomized weight -loss intervention among adults. Journal of medical Internet 
research. 2011;13(4):e120.  
83. Antoni MH, Ironson G, Schneiderman N. Cognitive -Behavioral Stress Management.  New York: Oxford 
University Press; 2007.  
84. Evon DM, Simpson K, Kixmiller S, et al. A Randomized Controlled Trial of an Integrated Care 
Intervention to Increase Eligibility for Chronic Hepatitis C Treatment. Am.J.Gastroenterol. 
2011;106(10):1777 -1786.  
85. Evon DM, Golin CE, Fried MW, Keefe FJ. Chronic hepatitis C and antiviral treatment regimens: where 
can psychology contribute? J.Consult Clin. Psychol. 2013;81(2):361- 374. 
86. Evon DM. Incorporating patient -reported outcomes into hepatitis C virus treatment studies. Clinical 
gastroenterology and hepatology : the official clinical practice journal of the American 
Gastroenterological Association. 2 014;12(8):1360- 1362.  
87. Evon DM, Esserman DA, Bonner JE, Rao T, Fried MW, Golin CE. Adherence to PEG/ribavirin 
treatment for chronic hepatitis C: prevalence, patterns, and predictors of missed doses and 
nonpersistence. J.Viral Hepat. 2013;20(8):536- 549. 
88. Evon DM, Golin CE, Stoica T, et al. What's Important to the Patient? Informational Needs of Patients 
Making Decisions About Hepatitis C Treatment. The patient. 2016.  
89. Evon DM, Golin CE, Stewart P, et al. Patient engagement and study design of PROP UP : A multi -site 
patient -centered prospective observational study of patients undergoing hepatitis C treatment. 
Contemporary clinical trials. 2017;57:58 -68. 
VC-CBCS Study protocol v 7.0—16Nov 2021  
 90. Ward BW, Schiller JS. Prevalence of multiple chronic conditions among US adults: estimates from t he 
National Health Interview Survey, 2010. Preventing chronic disease. 2013;10:E65.  
91. Rounsaville BJ, Carroll KM, Onken LS. A Stage Model of Behavioral Therapies Research: Getting 
Started and Moving on From Stage I. Clnical Psychology: Science and Practi ce. 2001;8(2):133- 142. 
92. Lattie EG, Antoni MH, Fletcher MA, et al. Stress management skills, neuroimmune processes and fatigue levels in persons with chronic fatigue syndrome. Brain, behavior, and immunity. 2012;26(6):849-
858. 
93. Edinger JD, Carney CE. Overcoming Insomnia: A cognitive- behavioral approach (Therapist Guide).  
New York: Oxford University Press; 2008.  
94. Linehan MM. Skills Training Manual for Treatment of Borderline Personality Disorder.  New York, NY: 
Guilford Press; 1993.  
95. Reilly PM, Sho pshire MS. Anger Management for Substance Abuse and Mental Health Clients: A 
Cognitve Behavioral Therapy Manual.  Vol DHHS Pub No.(SMA) 02 -3661. Rockville, MD: Center for 
Substance Abuse Treatment, Substance Abuse and Mental Health Services Adminstration; 2002.  
96. Safren SA, Otto MW, Worth J. Life -Steps:Applying Cognitive Behavioral Therapy to HIV Medication 
Adherence. Cognitive and Behavioral Practice. 1999;6:332 -341. 
97. Fisher JD, Fisher WA, Amico KR, Harman JJ. An information -motivation -behavioral skill s model of 
adherence to antiretroviral therapy. Health Psychol. 2006;25(4):462- 473. 
98. Cohen J. A power primer. Psychol Bull. 1992;112(1):155 -159. 
99. Horvath AO, Greenberg LS. The working alliance: Theory, research, and practice.  Oxford England: 
John Wil ey & Sons; 1994.  
100. Pence BW, Gaynes BN, Whetten K, Eron JJ, Jr., Ryder RW, Miller WC. Validation of a brief screening 
instrument for substance abuse and mental illness in HIV -positive patients. 
J.Acquir.Immune.Defic.Syndr. 2005;40(4):434- 444. 
101. Mayberry LS, Osborn CY. Empirical validation of the information -motivation- behavioral skills model of 
diabetes medication adherence: a framework for intervention. Diabetes Care. 2014;37(5):1246- 1253.  
102. https://www.mov e.va.gov/
. 2018. Accessed July 1, 2018, 2018.  
103. https://www.choosemyplate.gov/ . Accessed July 1, 2018, 2018.  
104. Lai M, Kasaraneni A. The Liver Healing Diet.  Ulysses Press; 2015.  
105. Morland LA, Poizner JM, Williams KE, Masino TT, Thorp SR. Home -based clinical video 
teleconferencing care: Clinical considerations and future directions. International review of psychiatry 
(Abingdon, England). 2015;27(6):504 -512. 
106. Stagl JM, Antoni MH, Lechner SC, et al. Randomized controlled trial of cognitive behavioral stress management in breast cancer: a brief report of effects on 5- year depressive symptoms. Health 
psychology : official journal of the Division of Health Psychology, American Psychological Association. 2015;34(2):176 -180. 
107. Stagl JM, Bouchard LC, Lechner SC, et al. Long- term psychological benefits of cognitive- behavioral 
stress management for women with breast cancer: 11- year follow -up of a randomized controlled trial. 
Cancer. 2015;121(11):1873- 1881.  
108. Stagl JM, Lechner SC, Carver CS, et al. A randomized controlled trial of cognitive- behavioral stress 
management in breast cancer: survival and recurrence at 11 -year follow -up. Breast cancer research 
and treatment. 2015;154(2):319- 328. 
109. Andersen BL, Yang HC, Farrar WB, et al. Psychologic intervention improves survival for breast cancer 
patients: a randomized clinical trial. Cancer. 2008;113(12):3450- 3458.  
110. MacKenzie KL, WJ., ed A Developmental Model for Br ief Group Therapy: Advances in Group Therapy:  
Integrating Research and Practice.  New York: International Universities Press; 1983. Dies RM, KR, ed.  
111. Joyce ASM -S, Rebecca; Tasca, Giorgio A.; Ogrodniczuk, John S. . Factor Structure and Validity of the 
Therapeutic Factors Inventory -Short Form. Group Dynamics Theory Research and Practice. 
2011;15(3):201 -219. 
112. Redeker NS, Anderson R, Bakken S, et al. Advancing Symptom Science Through Use of Common 
Data Elements. Journal of nursing scholarship : an offic ial publication of Sigma Theta Tau International 
Honor Society of Nursing. 2015;47(5):379 -388. 
113. Moore SM, Schiffman R, Waldrop -Valverde D, et al. Recommendations of Common Data Elements to 
Advance the Science of Self -Management of Chronic Conditions. Journal of nursing scholarship : an 
official publication of Sigma Theta Tau International Honor Society of Nursing. 2016;48(5):437 -447. 
114. Medicine USNLo. BRICS NINR Demographics. 2016. Accessed October 4, 2017.  
VC-CBCS Study protocol v 7.0—16Nov 2021  
 115. Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress. J Health Soc Behav. 
1983;24(4):385 -396. 
116. (CDC) CfDCaP. Behavioral Risk Factor Surveillance System Survey Data. Atlanta, Georgia:: 
Department of Health and Human Services; 2006.  
117. Mollayeva T, Thurairajah P, Burton K, Mollayeva S, Shapiro CM, Colantonio A. The Pittsburgh sleep quality index as a screening tool for sleep dysfunction in clinical and non- clinical samples: A systematic 
review and meta -analysis. Sleep medicine reviews. 2016;25:52 -73. 
118. Schrepf A, Clevenger L, Christensen D, et al. Cortisol and inflammatory processes in ovarian cancer patients following primary treatment: relationships with depression, fatigue, and disability. Brain, 
behavior, and immunity. 2013;30 Suppl:S126 -134. 
119. Lutgendorf SK, Wei nrib AZ, Penedo F, et al. Interleukin- 6, cortisol, and depressive symptoms in ovarian 
cancer patients. Journal of clinical oncology : official journal of the American Society of Clinical 
Oncology. 2008;26(29):4820- 4827.  
120. Phillips KM, Antoni MH, Lechner  SC, et al. Stress management intervention reduces serum cortisol and 
increases relaxation during treatment for nonmetastatic breast cancer. Psychosom.Med. 2008;70(9):1044 -1049.  
121. Wood P. Salivary steroid assays -  research or routine? Annals of clinical  biochemistry. 2009;46(Pt 
3):183 -196. 
122. Cella D, Riley W, Stone A, et al. The Patient -Reported Outcomes Measurement Information System 
(PROMIS) developed and tested its first wave of adult self -reported health outcome item banks: 2005-
2008. Journal of c linical epidemiology. 2010;63(11):1179 -1194.  
123. Reeve BB, Hays RD, Bjorner JB, et al. Psychometric evaluation and calibration of health -related quality 
of life item banks: plans for the Patient -Reported Outcomes Measurement Information System 
(PROMIS). Med.Care. 2007;45(5 Suppl 1):S22- S31. 
124. Evon DM, Amador J, Stewart P, et al. Psychometric properties of the PROMIS short form measures in a U.S. cohort of 961 patients with chronic hepatitis C prescribed direct acting antiviral therapy. 
Alimentary pharmacology & therapeutics. 2018;47(7):1001- 1011.  
 
 
 
 
 
 